H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...